Physician profile
Travis Senor
NPI 1316602246
$3,734.95
in general payments reported to CMS, 2019-2025
30 companies · $3,403 in 2025
The $3,403 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $332 · 2025: $3,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,625 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,625.46 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $875.28 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $310.00 | 2025 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $304.45 | 2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $245.65 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $224.31 | 2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $220.62 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $193.88 | 2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $186.43 | 2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $161.39 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $151.81 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $146.07 | 2025 | |
| Novo Nordisk INC | $141.64 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $76.13 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $66.10 | 2025 | Trintellix |
| Livanova USA, INC. | $61.30 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $44.62 | 2024 | Cologuard Collection Kit |
| Corium, LLC | $40.78 | 2025 | Azstarys |
| Tris Pharma INC | $39.68 | 2025 | Dyanavel Xr |
| Lilly USA, LLC | $33.84 | 2024-2025 | Amyvid, Kisunla, Zepbound |
| Viiv Healthcare Company | $33.30 | 2024 | Apretude |
| Eisai INC. | $20.97 | 2024 | |
| Abiomed | $20.57 | 2024 | Impella |
| Noven Therapeutics, LLC | $20.04 | 2025 | Xelstrym |
| Nevro Corp. | $19.99 | 2024 | Senza |
| Almatica Pharma LLC | $18.98 | 2025 | Loreev Xr |
| Astellas Pharma US INC | $18.25 | 2024 | Veozah |
| Dexcom, INC. | $15.70 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $15.46 | 2024 | Capvaxive, Vaxelis, Gardasil |
| Kowa Pharmaceuticals America, INC. | $14.21 | 2025 | Zoryve |
| Bausch Health US, LLC | $13.50 | 2025 | Wellbutrin, Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Senor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.